BioSpace News Archive

PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals as a very limited distribution partner for the novel drug GIVLAARI™ (givosiran)

Growth charts, hormones, risky behaviors … pediatricians have a lot to cover in the 20 minutes they spend with their patients, and yet a simple conversation can help thwart a wayward youthful trajectory.

For people in the Mercer/Bucks County region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis and pulmonary fibrosis, Capital Health is launching its new Pulmonary Rehabilitation Program in December.

Fertility and wellness company announces additional funding to sell directly to U.S. employers with 15 new customers and counting.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, announced today that Elan Ezickson, has joined the Company’s Board of Directors.

Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN). (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced that it has entered into definitive securities purchase agreements with certain institutional investors to purchase in a registered direct offering priced at-the-market 6,266,787 shares of the Company’s common stock, at a purchase price of $0.4335 per share, for aggregate gross proceeds of approximately $2.72 million

Well-established medical guidelines recommend biomarker testing for all patients with metastatic colon cancer, but new research shows this may not be consistent with actual patterns of care

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, presented updated clinical results from its Phase 2b trial of MDNA55, in patients with recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer. T

Eye tracking startup transforms mobile devices into assistive technology tools, making eye-powered communication more accessible to millions in need